Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the findings of the Phase Ib/II FORT-2 (NCT03473756) study, which assesses the safety and efficacy of rogaratinib with atezolizumab in patients with urothelial cancer. Patients were enrolled based on overexpression of FGFR1 or FGFR3 instead of mutational status. In this study, the overall response rate (ORR) of the combination was superior to atezolizumab monotherapy. The safety profile of rogaratinib with atezolizumab was additionally comparable to that of rogaratinib and atezolizumab treatment separately. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.